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ABSTRACT
Over 100,000 cases of COVID-19 patients infected
with the novel corona virus SARS-COV-2 have been
reported worldwide in approximately 2 months,
resulting in over 3000 deaths. Potential therapeutic
strategies, including remdesivir, chloroquine
phosphate, abidol, lopinavir/ritonavir, plasma,
antibody, vaccine and stem cells are discussed in this
review. With the number of patients increasing
daily, there is an urgent need for effective
therapeutic intervention.

pneumonia was named Corona Virus Disease 2019
(COVID-19). World Health Organization (WHO)
declared COVID-19 a Public Health Emergency of
International Concern on January 31, and, as of
March 2020, the virus has infected >90,000 people,
and killed >3,100 worldwide1. With the number of
patients increasing daily, there is an urgent need for
effective therapeutic intervention. In this article, we
will discuss several therapeutic strategies against
COVID-19 infection.
2. Nucleotide analogs
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1. Introduction
Since the beginning of December 2019, numerous
hospitals in Wuhan, China have reported an
increasing number of patients with pneumonia due
to the infection with an unknown virus. The virus,
first named 2019 novel Corona Virus (2019-nCoV),
was later changed to Severe Acute Respiratory
Syndrome Corona Virus 2 (SARS-COV-2), and the
www.discoveriesjournals.org/discoveries

The first case of COVID-19 in the United States was
confirmed on January 20, 2020, by qPCR assay with
samples from the patient’s nasopharyngeal and
oropharyngeal swabs. Probes were based on
genomic sequence of 2019-nCoV released by
scientists from China. After the development of
radiographic pneumonia, the patient was treated with
remdesivir intravenously and almost all clinical
symptoms resolved the following day2. Remdesivir
(Figure 1) is a nucleotide analog originally
developed by Gilead as a drug against Ebola virus.
Mechanistically, it inhibits RNA-dependent RNA
synthetase (RdRp) with completed Phase I and/or II
clinical trials3,4. Therefore, Gilead has been working
with China since February 2020 to conduct a phase 3
randomized, double-blinded, placebo-controlled,
multicenter trial to determine the safety and efficacy
of remdesivir on hospitalized patients with severe
COVID-195. The treatment was designed as 200 mg
of remdesivir on day 1 followed by 100 mg/day for
9 days. The study is expected to be completed by
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Figure 1. The structure of remdesivir, a nucleoside analog with antiviral activity.
Results from experiments conducted on Vero E6 cells indicate that the EC90 for SARS-COV-2 is 1.76μM4.

May 1, 20206. In addition, other antiviral nucleotide
analogs such as fapivir and ribavirin are undergoing
clinical trials. Fapivir is a drug approved in Japan for
flu treatment.

it also significantly reduced the pathological effect
of the virus9. A randomized multi-center controlled
clinical trial wtih Abidol in patients with COVID-19
has started in Xiangya Hospital in China, which has
been registered in the US clinical trial database10.

3. Chloroquine phosphate
5. Lopinavir/ritonavir
Chloroquine phosphate is an antimalarial drug. By
increasing the pH of the nucleus, it can inhibit both
the virus-host cell interaction and the pH-dependent
virus replication7. The results from in vitro studies
suggest that chloroquine can actively inhibit SARSCOV-24. Both animal experiments and clinical trials
are currently in progress. Results from preliminary
clinical trials show that chloroquine phosphate has
promising effects on patients with COVID-19. Of
note, it has been reported that chloroquine may
cause adverse reactions such as ocular disorders,
immune system disorders, ear and labyrinth
disorders, cardiac disorders, etc.8, therefore
precautions and further testing are needed for the
safe and effective treatment in COVID-19 patients.
4. Abidol
Abidol is a broad-spectrum antiviral drug. By
inhibiting the fusion between the influenza virus and
host cells, it can inhibit virus replication. It has been
used to prevent/treat both SARS and Middle East
Respiratory Syndrome (MERS). According to an
online report, Abidol in the concentration range of
10-30μM not only inhibited COVID-19 duplication,
www.discoveriesjournals.org/discoveries

Lopinavir/ritonavir is a combination of drugs mainly
used for AIDS treatment. Lopinavir inhibits viral
protease resulting in immature/non-infectious virus
particles; ritonavir inhibits the degradation of
lopinavir in the liver and thereby extends lopinavir’s
half-life. Results from in vitro studies showed that
lopinavir/ritonavir can inhibit the replication of both
MERS and SARS11. However, whether they can
inhibit COVID-19 is unknown. Therefore, a clinical
trial to use lopinavir/ritonavir for COVID-19
treatment will be launched soon in a hospital in
Wuhan, China. In addition, since darunavir (trade
name: Prozekal) is another protease inhibitor used
for HIV treatment, a combination of darunavir and
ritonavir could also be a potential treatment of
COVID-19, especially since darunavir has been
approved in China since 2018 for HIV treatment.
6. Plasma
The company CNBG claimed on February 13, 2020,
that plasma from recovered patients was used to
successfully cure 11 critically ill patients with
COVID-1912. The donated plasma with high-titer of
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KEY POINTS
◊ The recent COVID-19 disease is due to the infection with the new coronavirus, SARSCoV-2, causing a pandemic and necessitates the development of effective
therapeutics.
◊ Many clinical trials are initiated worldwide. Potential therapeutics, including
nucleotide analogs，chloroquine phosphate，abidol，lopinavir/ritonavir，plasma
antibodies，vaccines, stem cells are among the most important strategies to be
developed.
SARS-COV-2 antibodies was confirmed without
pathogens and with virus inactivation12. Of note, 12
to 24 hours post-treatment, the major inflammation
symptoms decreased significantly with increased
lymphocytes counts and blood oxygen saturation.
Improved vital signs were also observed. Currently,
although the exact underlying mechanisms are
unknown, it is reasonable to speculate that the
antibodies may bind the virus and prevent virus-host
cell interaction, and therefore prevent infection. In
addition, NK cells and other immune cells may also
be involved in clearing the virus by antibodydependent cell-mediated cytotoxicity. However, the
potential risks associated with plasma usage,
including pathogen transmission and allergic
reaction, should be considered, and therefore this
strategy may only be applied for a clinical
emergency following standardized procedures. On
the other hand, specific immunoglobulin could be a
better option for treating critically ill patients with
SARS-COV-2 infection.

it usually takes an extended period of time to
generate monoclonal antibodies for a new pathogen
that can be used clinically.
Regeneron
Pharmaceuticals
is
using
VelociSuite technology with a humanized mouse
immune system to rapidly develop innovative
antibodies for the treatment of virus sepsis. This
strategy has shown positive results in clinical trials
using antibodies to treat Ebola13. The German
company Inflarx has developed a monoclonal
antibody against the human C5a molecule. By
specifically binding and inhibiting C5a-mediated
biological functions, including the release of
neutrophil chemotaxis and intra-cellular lysozyme,
the antibodies can limit excessive inflammation
without inhibiting immune function. Clinical trials
on this antibody are now underway in China to
potentially reduce both lung damage and death
caused by sepsis infection14.

7. Antibodies

There are now at least four candidate vaccines
against the sepsis that are under development.
Clinical trials on the most promising vaccine
candidates may start in three to four months.
However, it usually takes more than a year for a
vaccine to become clinically applicable15.

Specific neutralizing antibodies against viral surface
proteins may bind and prevent the virus from
entering the host epithelial cells and subsequently
prevent virus amplification. On the other hand, nonneutralizing antibodies may bind the virus and
activate the immune cells (mainly macrophages) to
engulf and clear the virus. However, excessive
activation of these non-specific immune cells may
cause the release of a large number of proinflammatory factors leading to cytokine storm and
sepsis-related death. Therefore, non-neutralizing
antibodies play an antiviral role in the early stages
but may cause lung damage at later stages. However,

www.discoveriesjournals.org/discoveries

8. Vaccines

9. Stem cells
Due to the self-renewal and multi-directional
differentiation capability of mesenchymal stem cells,
they can be differentiated to produce multifunctional
cells. In damaged lung tissues, stem cells may be
able to replenish bronchial epithelial and endothelial
cells after the clearance of viral infection. They may
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also stabilize the pulmonary micro blood vessel and
alveolar epithelial cell barriers. These effects could
enhance the patient's immunity, alleviate pneumonia,
and prevent secondary infections. As of February 14,
2020, more than 4 such projects have been approved
for the treatment of COVID-19 in China, and
another one has applied to the U.S. Food and Drug
Administration (FDA) for emergency approval16.
10. Others
Other clinical trials of treatment options are also on
the agenda. A search with the word “COVID-19” in
the
China
Clinical
Trials
Registry
(http://www.chictr.org.cn) revealed that 218 clinical
trials have been registered on the platform as of
March 9. Dozens of clinical trials have also been
registered on the international platform of clinical
trials (https://clinicaltrials.gov/). Recently, as a key
target for therapeutic intervention, the cryo-EM
structure of the CoV spike protein in its trimer form
has been elucidated, which may further contribute to
therapeutic designs in the near future17.
11. Conclusion
Currently, remdesivir appears to be the most
promising drug for the treatment of pneumonia
caused by COVID-19 pneumonia. Many other
agents or strategies are being tested for the treatment
of patients with COVID-19. However, double-blind,
randomized controlled trials are required to
investigate their safety and efficacy.
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